nach oben

Pituitary

Erschienen in:

01.04.2016

Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas

verfasst von: V. Larouche, J. A. Correa, P. Cassidy, C. Beauregard, N. Garfield, J. Rivera

Erschienen in: Pituitary | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Prolactin can affect autoimmune response and evidence suggests that hyperprolactinemia can primarily precipitate autoimmunity. We postulate that patients with prolactinomas are more prone to autoimmune disease (AID).

Methods

We conducted a retrospective case–control study comparing prevalence of AID in 100 prolactinoma patients (PRL-P, cases) and 100 age- and gender-matched non-functioning pituitary adenoma patients (NFPA-P, controls) assessed at the Neuroendocrine Clinics of the McGill University Health Centre between January 2005 and December 2014. Comparisons were done using a conditional logistic regression (CLR) analysis. Multiple imputation was used to account for missing data values.

Results

Sixty-eight women and 32 men were in each group. Median age was 37 years for PRL-P and 46 years for NFPA-P. AID was diagnosed in 28/100 cases and 16/100 controls. Autoimmune thyroid disease was the most common AID reported in both groups, representing 70 and 61 % of the AID diagnoses respectively. CLR analysis revealed a multiplicative interaction effect between AID prevalence and age (p 0.004). Odds ratios for AID in PRL-P compared to NFPA-P increase with age and become significant at age 43, reaching 4.17 (95 % CI 1.26, 13.82) at age 45 and 8.09 (95 % CI 1.96, 33.43) at age 50 (p 0.05).

Conclusion

Our data showed a higher prevalence of AID in both PRL-P and NFPA-P than in a reference population. In both groups, prevalence of AID increased with age, given a multiplicative interaction effect. A significant higher prevalence of autoimmunity in PRL-P compared with NFPA-P occurs after age 43. These associations may have significant implications for the management of prolactinoma patients.

De Bellis A et al (2005) Prolactin and autoimmunity. Pituitary 8(1):25–30CrossRefPubMed

Jara L et al (2011) Prolactin and autoimmunity. Clin Rev Allergy Immunol 40(1):50–59CrossRefPubMed

Matera L et al (2000) Prolactin in autoimmunity and antitumor defence. J Neuroimmunol 109:47–55CrossRefPubMed

Orbach H et al (2012) Prolactin and autoimmunity: hyperprolactinemia correlates with serositis and anemia in SLE patients. Clin Rev Allergy Immunol 42(2):189–198CrossRefPubMed

Shelly S, Boaz M, Orbach H (2012) Prolactin and autoimmunity. Autoimmun Rev 11(6):465–470CrossRef

Vera-Lastra O, Jara LJ, Espinoza LR (2002) Prolactin and autoimmunity. Autoimmun Rev 1(6):360–364CrossRefPubMed

Alvarez-Nemegyei J et al (1998) Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study. Lupus 7(6):414–419CrossRefPubMed

Buskila D et al (1996) No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J Rheumatol 23(4):629–632PubMed

Jacobi AM et al (1998) Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus 10(8):554–561CrossRef

10.

Jara LJ et al (1998) Prolactin and interleukin-6 in neurophsychiatric lupus erythematosus. Clin Rheumatol 17(2):110–114CrossRefPubMed

11.

Karimifar M et al (2013) Correlation of serum prolactin levels and disease activity in systemic lupus erythematosus. Rheumatol Int 33:511–516CrossRefPubMed

12.

Leaños-Miranda A, Cárdenas-Mondragón G (2006) Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity. Rheumatology (Oxford) 45(1):97–101CrossRef

13.

McMurray RW et al (1995) Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 22(11):2084–2091PubMed

14.

Pacilio M et al (2001) Elevated bioactive prolactin levels in systemic lupus erythematosus—association with disease activity. J Rheumatol 28(10):2216–2221PubMed

15.

Peeva E et al (2011) Prolactin, systemic lupus erythematosis, and autoreactive B cells: lessons learnt from murine models. Clin Rev Allergy Immunol 40(1):8–15CrossRefPubMed

16.

Szyper-Kravitz M et al (2005) The neuroendocrine-immune interactions in systemic lupus erythematosus: a basis for understanding disease pathogenesis and complexity. Rheum Dis Clin North Am 31(1):161–175CrossRefPubMed

17.

Rezaieyazd Z, Hesamifard A (2006) Correlation between serum prolactin levels and lupus activity. Rheumatol Int 26(11):1036–1039CrossRef

18.

Berczi I et al (1987) Decreased bioactivity of circulating prolactin in patients with rheumatoid arthritis. Br J Rheumatol 26(6):433–436CrossRefPubMed

19.

Chikanza I (1996) The neuroendocrine immunology of rheumatoid arthritis. Baillieres Clin Rheumatol 10(2):273–293CrossRefPubMed

20.

Fojtikova M et al (2010) Elevated prolactin levels in patients with rheumatoid arthritis: association with disease activity and structural damage. Clin Exp Rheumatol 28(6):849–854PubMed

21.

Guttierrez M et al (1999) Hypothalamic-pituitary-adrenal axis function in patients with active rheumatoid arthritis: a controlled study using insulin hypoglycemia stress test and prolactin stimulation. J Rheumatol 26(2):277–281

22.

Mateo L et al (1998) High serum prolactin levels in men with rheumatoid arthritis. J Rheumatol 25(11):2077–2082PubMed

23.

McMurray RW et al (1995) Elevated serum prolactin levels in children with juvenile rheumatoid arthritis and antinuclear antibody seropositivity. J Rheumatol 22(8):1577–1580PubMed

24.

Nagy E et al (1991) Prolactin deficiency in rheumatoid arthritis. J Rheumatol 18(11):1662–1668PubMed

25.

Neidhart M, Gay RE, Gay S (1999) Prolactin and prolactin-like polypeptides in rheumatoid arhtritis. Biomed Pharmacother 53:218–222CrossRefPubMed

26.

El Miedany Y et al (2004) Hyperprolactinemia in Sjogren’s syndrome: a patient subset or a disease manifestation? Joint Bone Spine 71:203–208CrossRefPubMed

27.

Czuwara-Ladykowska J et al (2006) Prolactin synthesis by lymphocytes from patients with systemic sclerosis. Biomed Pharmacother 60(4):152–155CrossRefPubMed

28.

Hilty C et al (2000) Altered diurnal rhythm of prolactin in systemic sclerosis. J Rheumatol 27(9):2160–2165PubMed

29.

Kucharz EJ et al (1996) High serum level of prolactin in patients with systemic sclerosis. Clin Rheumatol 15:314CrossRefPubMed

30.

Mirone L, Barini A, Barini A (2006) Androgen and prolactin (PRL) levels in systemic sclerosis: relationship to disease severity. Ann N Y Acad Sci 1069:257–262CrossRefPubMed

31.

Straub RH et al (1997) High prolactin and low dehydroepiandrosterone sulphate serum levels in patients with severe systemic sclerosis. Br J Rheumatol 36(4):426–432CrossRefPubMed

32.

Eulry F (1996) Blood prolactin under the effect of protirelin in spondylarthropathies. Treatment trial of 4 cases of reactive arthritis and 2 cases of psoriatic arthritis with bromocriptine. Ann Med Interne (Paris) 147(1):15–19

33.

Kokot I et al (2013) Prolactin as an immunomodulatory factor in psoriatic arhtritis. Postepy Hig Med Dosw 67:1265–1272CrossRef

34.

Cejkova P, Fotjikova M (2009) Immunomodulatory role of prolactin in diabetes development. Autoimmun Rev 9:23–27CrossRefPubMed

35.

Barnett AH, Gould MI (1978) Hyperprolactinemia and Graves’ disease. Lancet 2(8101):1210CrossRefPubMed

36.

Tamai H et al (2010) Heterogeneity of serum prolactin in patients with menstrual disorder in conjunction with hyperthyroxinemia. J Endocrinol Invest 14(8):679–684CrossRef

37.

Hekimsoy Z et al (2010) The prevalence of hyperprolactinaemia in overt and subclinical hypothyroidism. Endocr J 57(12):1011–1015CrossRefPubMed

38.

Legakis I et al (2001) Elevated prolactin to cortisol ratio and polyclonal autoimmune activation in Hashimoto’s thyroiditis. Horm Metab Res 33(10):585–589CrossRefPubMed

39.

Notsu K et al (1997) Incidence of hyperprolactinemia in patients with Hashimoto’s thyroiditis. Endocr J 44(1):89–94CrossRefPubMed

40.

Pelkonen R, Salmi J, Lamber BA (1982) Interrelationship between TSH- and prolactin secretion in patients with prolactinoma and autoimmune thyroiditis. Acta Endocrinol (Copenh) 100(2):184–188

41.

Sayki Arslan M et al (2013) Hyperprolactinaemia associated with increased thyroid volume and autoimmune thyroiditis in patients with prolactinoma. Clin Endocrinol (Oxf) 79(6):882–886CrossRef

42.

Akçay G et al (1996) Pituitary macroadenoma in Addison’s disease. J Int Med Res 24(2):221–227PubMed

43.

Lever EG, McKerron CG (1984) Auto-immune Addison’s disease associated with hyperprolactinaemia. Clin Endocrinol (Oxf) 21(4):451–457CrossRef

44.

Lever EG (1986) Addison’s disease with hyperprolactinemia. Fertil Steril 46(3):537PubMed

45.

Delvecchio M et al (2014) Prolactin may be increased in newly diagnosed celiac children and adolescents and decreases after 6 months of gluten-free diet. Horm Res Paediatr 81:309–313CrossRefPubMed

46.

Kapur G et al (2004) Serum prolactin in coealiac disease. J Trop Pediatr 50(1):37–40CrossRefPubMed

47.

Refien R et al (1997) Serum prolactin in coealiac disease: a marker for disease activity. Arch Dis Child 77(2):155–157CrossRef

48.

Bergh F et al (2006) Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis—reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol 6:19CrossRef

49.

Da Costa R et al (2011) Ferritin and prolactin levels in multiple sclerosis. Isr Med Assoc J 13(2):91–95PubMed

50.

Harichian MH et al (2006) Serum prolactin levels in patients with multiple sclerosis: a case control study. Med Sci Monit 12(4):177–180

51.

Kira J et al (1991) Hyperprolactinemia in multiple sclerosis. J Neurol Sci 102(1):61–66CrossRefPubMed

52.

Markianos M et al (2010) Serum and cerebrospinal fluid prolactin levels in male and female patients with clinically-isolated syndrome or relapsing-remitting multiple sclerosis. J Neuroendocrinol 22(6):503–508CrossRefPubMed

53.

Nociti V et al (2010) Multiple sclerosis attacks triggered by hyperprolactinemia. J Neurooncol 98(3):407–409CrossRefPubMed

54.

Zhornitsky S et al (2013) Prolactin in multiple sclerosis. Mult Scler 19(1):15–23CrossRefPubMed

55.

Chikanza I (1999) Prolactin and neuroimunomodulation: in vitro and in vivo observations. Ann N Y Acad Sci 876:119–130CrossRefPubMed

56.

Breslow NE, Day NE (1980) Statistical methods in cancer research. The analysis of case-control studies, IARC Scientific publications No. 32, vol 1. International Agency for Research on Cancer, Lyon, pp 247–279

57.

Rubin DB (1987) Multiple imputation for nonresponse in surveys. John Wiley & Sons, New YorkCrossRef

58.

Raghunathan TE, Solenberger PW, Van Hoewyk JV (2002) IVEware: imputation and variance estimation software user's guide. Ann Arbor, MI, Institute for Social Research, University of Michigan. http://www.isr.umich.edurs/c/smp/ive/

59.

Allison PD (2009) Sage university paper series on quantitative applications in the social sciences, series no (07-136). Thousand Oaks, CA: Sage

60.

Graham JW, Olchowski AE, Gilreath TD (2007) How many imputations are really needed? Some practical clarifications of multiple imputation theory. Prev Sci 8(3):206–213CrossRefPubMed

61.

Zerhouni EA et al (2005) Progress in autoimmune diseases research. National Institutes of Health - Autoimmune Diseases Coordinating Committee. Bethesda, MD. https://www.niaid.nih.gov/topics/autoimmune/Documents/adccfinal.pdf

62.

Duncan GS et al (1996) The transcription factro interferon regulatory factor-1 is essential for natural killer cell function in vivo. J Exp Med 184:2043–2048CrossRefPubMed

63.

Tomio A et al (2008) Prolactin can modulate CD4+ T-cell response through receptor-mediated alterations in the expression of T-bet. Immunol Cell Biol 86:616–621CrossRefPubMed

Titel: Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas
verfasst von: V. Larouche
J. A. Correa
P. Cassidy
C. Beauregard
N. Garfield
J. Rivera
Publikationsdatum: 01.04.2016
Verlag: Springer US
Erschienen in: Pituitary / Ausgabe 2/2016
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-015-0699-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease

Intraoperative magnetic resonance imaging assessment of non-functioning pituitary adenomas during transsphenoidal surgery

A comparative analysis of ESM-1 and vascular endothelial cell marker (CD34/CD105) expression on pituitary adenoma invasion

Significant improvement of intractable headache after transsphenoidal surgery in patients with pituitary adenomas; preoperative neuroradiological evaluation and intraoperative intrasellar pressure measurement

Prof. Jens Sandahl Christiansen

Algorithm development and the clinical and economic burden of Cushing’s disease in a large US health plan database